Cargando…
Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer
BACKGROUND: Perioperative fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) improves prognosis in locally advanced gastric cancer (LAGC). Neutrophil-to-lymphocyte (NLR), lymphocyte-to-monocyte (LMR), and platelet-to-lymphocyte (PLR) ratios are prognostic biomarkers but not predictive f...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305575/ https://www.ncbi.nlm.nih.gov/pubmed/36051098 http://dx.doi.org/10.4251/wjgo.v14.i7.1307 |
_version_ | 1784752359734247424 |
---|---|
author | Tomás, Tiago Cruz Eiriz, Inês Vitorino, Marina Vicente, Rodrigo Gramaça, João Oliveira, Alicia Guadalupe Luz, Paulo Baleiras, Mafalda Spencer, Ana Sofia Costa, Luísa Leal Liu, Patrícia Mendonça, Joana Dinis, Magno Padrão, Teresa Correia, Marisol Atalaia, Gonçalo Silva, Michelle Fiúza, Teresa |
author_facet | Tomás, Tiago Cruz Eiriz, Inês Vitorino, Marina Vicente, Rodrigo Gramaça, João Oliveira, Alicia Guadalupe Luz, Paulo Baleiras, Mafalda Spencer, Ana Sofia Costa, Luísa Leal Liu, Patrícia Mendonça, Joana Dinis, Magno Padrão, Teresa Correia, Marisol Atalaia, Gonçalo Silva, Michelle Fiúza, Teresa |
author_sort | Tomás, Tiago Cruz |
collection | PubMed |
description | BACKGROUND: Perioperative fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) improves prognosis in locally advanced gastric cancer (LAGC). Neutrophil-to-lymphocyte (NLR), lymphocyte-to-monocyte (LMR), and platelet-to-lymphocyte (PLR) ratios are prognostic biomarkers but not predictive factors. AIM: To assess blood ratios’ (NLR, LMR and PLR) potential predictive response to FLOT and survival outcomes in resectable LAGC patients. METHODS: This was a multicentric retrospective study investigating the clinical potential of NLR, LMR, and PLR in resectable LAGC patients, treated with at least one preoperative FLOT cycle, from 12 Portuguese hospitals. Means were compared through non-parametric Mann-Whitney tests. Receiver operating characteristic curve analysis defined the cut-off values as: High PLR > 141 for progression and > 144 for mortality; high LMR > 3.56 for T stage regression (TSR). Poisson and Cox regression models the calculated relative risks/hazard ratios, using NLR, pathologic complete response, TSR, and tumor regression grade (TRG) as independent variables, and overall survival (OS) as the dependent variable. RESULTS: This study included 295 patients (mean age, 63.7 years; 59.7% males). NLR was correlated with survival time (r = 0.143, P = 0.014). PLR was associated with systemic progression during FLOT (P = 0.022) and mortality (P = 0.013), with high PLR patients having a 2.2-times higher risk of progression [95% confidence interval (CI): 0.89-5.26] and 1.5-times higher risk of mortality (95%CI: 0.92-2.55). LMR was associated with TSR, and high LMR patients had a 1.4-times higher risk of achieving TSR (95%CI: 1.01-1.99). OS benefit was found with TSR (P = 0.015) and partial/complete TRG (P < 0.001). Patients without TSR and with no evidence of pathological response had 2.1-times (95%CI: 1.14-3.96) and 2.8-times (95%CI: 1.6-5) higher risk of death. CONCLUSION: Higher NLR is correlated with longer survival time. High LMR patients have a higher risk of decreasing T stage, whereas high PLR patients have higher odds of progressing under FLOT and dying. Patients with TSR and a pathological response have better OS and lower risk of dying. |
format | Online Article Text |
id | pubmed-9305575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-93055752022-08-31 Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer Tomás, Tiago Cruz Eiriz, Inês Vitorino, Marina Vicente, Rodrigo Gramaça, João Oliveira, Alicia Guadalupe Luz, Paulo Baleiras, Mafalda Spencer, Ana Sofia Costa, Luísa Leal Liu, Patrícia Mendonça, Joana Dinis, Magno Padrão, Teresa Correia, Marisol Atalaia, Gonçalo Silva, Michelle Fiúza, Teresa World J Gastrointest Oncol Retrospective Study BACKGROUND: Perioperative fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) improves prognosis in locally advanced gastric cancer (LAGC). Neutrophil-to-lymphocyte (NLR), lymphocyte-to-monocyte (LMR), and platelet-to-lymphocyte (PLR) ratios are prognostic biomarkers but not predictive factors. AIM: To assess blood ratios’ (NLR, LMR and PLR) potential predictive response to FLOT and survival outcomes in resectable LAGC patients. METHODS: This was a multicentric retrospective study investigating the clinical potential of NLR, LMR, and PLR in resectable LAGC patients, treated with at least one preoperative FLOT cycle, from 12 Portuguese hospitals. Means were compared through non-parametric Mann-Whitney tests. Receiver operating characteristic curve analysis defined the cut-off values as: High PLR > 141 for progression and > 144 for mortality; high LMR > 3.56 for T stage regression (TSR). Poisson and Cox regression models the calculated relative risks/hazard ratios, using NLR, pathologic complete response, TSR, and tumor regression grade (TRG) as independent variables, and overall survival (OS) as the dependent variable. RESULTS: This study included 295 patients (mean age, 63.7 years; 59.7% males). NLR was correlated with survival time (r = 0.143, P = 0.014). PLR was associated with systemic progression during FLOT (P = 0.022) and mortality (P = 0.013), with high PLR patients having a 2.2-times higher risk of progression [95% confidence interval (CI): 0.89-5.26] and 1.5-times higher risk of mortality (95%CI: 0.92-2.55). LMR was associated with TSR, and high LMR patients had a 1.4-times higher risk of achieving TSR (95%CI: 1.01-1.99). OS benefit was found with TSR (P = 0.015) and partial/complete TRG (P < 0.001). Patients without TSR and with no evidence of pathological response had 2.1-times (95%CI: 1.14-3.96) and 2.8-times (95%CI: 1.6-5) higher risk of death. CONCLUSION: Higher NLR is correlated with longer survival time. High LMR patients have a higher risk of decreasing T stage, whereas high PLR patients have higher odds of progressing under FLOT and dying. Patients with TSR and a pathological response have better OS and lower risk of dying. Baishideng Publishing Group Inc 2022-07-15 2022-07-15 /pmc/articles/PMC9305575/ /pubmed/36051098 http://dx.doi.org/10.4251/wjgo.v14.i7.1307 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Retrospective Study Tomás, Tiago Cruz Eiriz, Inês Vitorino, Marina Vicente, Rodrigo Gramaça, João Oliveira, Alicia Guadalupe Luz, Paulo Baleiras, Mafalda Spencer, Ana Sofia Costa, Luísa Leal Liu, Patrícia Mendonça, Joana Dinis, Magno Padrão, Teresa Correia, Marisol Atalaia, Gonçalo Silva, Michelle Fiúza, Teresa Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer |
title | Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer |
title_full | Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer |
title_fullStr | Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer |
title_full_unstemmed | Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer |
title_short | Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer |
title_sort | neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer |
topic | Retrospective Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305575/ https://www.ncbi.nlm.nih.gov/pubmed/36051098 http://dx.doi.org/10.4251/wjgo.v14.i7.1307 |
work_keys_str_mv | AT tomastiagocruz neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT eirizines neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT vitorinomarina neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT vicenterodrigo neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT gramacajoao neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT oliveiraaliciaguadalupe neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT luzpaulo neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT baleirasmafalda neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT spenceranasofia neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT costaluisaleal neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT liupatricia neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT mendoncajoana neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT dinismagno neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT padraoteresa neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT correiamarisol neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT atalaiagoncalo neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT silvamichelle neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer AT fiuzateresa neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer |